Donor Selection Based on Killer Cell Immunoglobulin–Like Receptor (KIR) Genotype May Improve Outcome After T-Cell–Replete Haploidentical Transplantation

Torı́o, Alberto; Pascual, María-Jesús; Vidales, Isabel; Ortiz, Macarena; Caballero, Abelardo; Heiniger, Ana Isabel

doi:10.1016/j.transproceed.2017.09.070

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTCy-haploBMT from non-first-degree relatives results is similar to those seen with first-degree relatives [12]. The impact of donor versus recipient killer cell immunoglobulin-like receptor (KIR)ligand mismatch in PTCy-haploSCT is still controversial [13][14][15][16].…”

Section: Donor Selection For Ptcy-haplosctmentioning

confidence: 87%

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

Sato

2019

Int J Hematol

View full text Add to dashboard Cite

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide has spread rapidly worldwide. This strategy was initially developed in the setting of bone marrow transplantation following nonmyeloablative conditioning. Recently, peripheral blood stem cell grafts and/or myeloablative conditioning regimen have been widely used. In Japan, prospective, multicenter, phase II studies have been conducted by the Japan Study Group for Cell Therapy and Transplantation to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haploPBSCT). In the first such study (JSCT Haplo 13 study), we demonstrated that PTCy-haploPBSCT after busulfan-based reduced-intensity conditioning (RIC) enables stable donor engraftment and low incidences of both acute and chronic graft-versus-host disease (GVHD). In the second (JSCT Haplo 14 study), we showed that both myeloablative conditioning (MAC) and RIC are valid options for PTCy-haploPBSCT. Emerging evidence, including our findings, suggests that donor type (HLA-haploidentical donor versus HLA-matched related or unrelated donor) may no longer be a significant predictor of transplant outcome.

show abstract

Section: Donor Selection For Ptcy-haplosctmentioning

confidence: 87%

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

Sato

2019

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…Solomon et al suggested selecting donors with KIR recipient‐ligand mismatches and the KIR B/x 2DS2 haplotype . Another small study found that donor presence of the AA or Bx haplotype or mismatches on KIR ligands were associated with decreased chronic GVHD . However, a recent EBMT retrospective study found that NK‐alloreactive donors were not associated with better outcomes in TCR haplo‐HCT with PTCy, and their results suggested that KIR‐ligand mismatching may even need to be avoided when peripheral blood CD34 + cells are selected as the graft source …”

Section: Nk Cell Alloreactivitymentioning

confidence: 99%

Donor selection for haploidentical hematopoietic cell transplantation‐ practice guidance

2018

View full text Add to dashboard Cite

Haploidentical hematopoietic cell transplantation (haplo‐HCT) using either T‐cell depletion or T‐cell repletion (Beijing protocol or post‐transplantation cyclophosphamide) has shown great advancements in recent years. Haplo‐HCT can achieve comparable outcomes for transplantation from matched sibling donors and unrelated donors and has been used increasingly worldwide. For almost every patient, multiple haploidentical donors are available. Therefore, it is necessary to choose the best donor. However, there is no universal consensus on donor selection. The aim of this review was to discuss the general principles of and controversial factors related to donor selection. Several principles have been widely accepted. For example, human leukocyte antigen disparity is no longer taken into account, donor‐specific antibodies should be avoided, and younger donors and ABO matches are preferred. However, factors such as donor gender, family relationship, cytomegalovirus serological status, and natural killer cell alloreactivity are still controversial. Moreover, the factors may depend on the transplantation regimen. Finally, we summarize practical points for donor selection according to different haplo‐HCT protocols.

show abstract

“…Human killer cell immunoglobulin‐like receptors (KIRs) are a subfamily of the immunoglobulin superfamily. The KIRs interact with their ligands (HLA class I molecules) to affect the function of Natural killer (NK) cells, and play an important role in health and disease, including the successful outcome of hematopoietic stem cell transplantation, infection disease and certain tumors . The KIRs have been shown to be highly polymorphic with different expression profiles, abundant alleles and variation of the gene copy number .…”

mentioning

confidence: 99%

Characterization of the novel KIR3DL2 allele, KIR3DL2113*

Chen

Wang

et al. 2020

HLA

View full text Add to dashboard Cite

show abstract

Donor Selection Based on Killer Cell Immunoglobulin–Like Receptor (KIR) Genotype May Improve Outcome After T-Cell–Replete Haploidentical Transplantation

Cited by 6 publications

References 12 publications

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

Donor selection for haploidentical hematopoietic cell transplantation‐ practice guidance

Characterization of the novel KIR3DL2 allele, KIR3DL2113*

Contact Info

Product

Resources

About

Donor Selection Based on Killer Cell Immunoglobulin–Like Receptor (KIR) Genotype May Improve Outcome After T-Cell–Replete Haploidentical Transplantation

Cited by 6 publications

References 12 publications

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

Donor selection for haploidentical hematopoietic cell transplantation‐ practice guidance

Characterization of the novel KIR3DL2 allele, KIR3DL2*113

Contact Info

Product

Resources

About

Characterization of the novel KIR3DL2 allele, KIR3DL2113*